Compounds > (3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid

(3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid and HIV-Associated-Lipodystrophy-Syndrome

(3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid has been researched along with HIV-Associated-Lipodystrophy-Syndrome* in 1 studies

Trials

1 trial(s) available for (3S-5S-6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3-5-dihydroxyhept-6-enoic-acid and HIV-Associated-Lipodystrophy-Syndrome

Article	Year
Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS (London, England), 2006, Aug-01, Volume: 20, Issue:12 We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients. Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; Cholesterol; Cholesterol, LDL; Endothelium; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; HIV-Associated Lipodystrophy Syndrome; Humans; Indoles; Treatment Outcome	2006

Article

Year

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.

AIDS (London, England), 2006, Aug-01, Volume: 20, Issue:12

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.

Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; Cholesterol; Cholesterol, LDL; Endothelium; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; HIV-Associated Lipodystrophy Syndrome; Humans; Indoles; Treatment Outcome

2006